Tumor Registry of Lymphatic Neoplasia

NCT00889798 | Completed

• 1 other identifier: IOM-TLN
• Study Type: observational
• Target: 3,795
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

Conditions

Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM)

Keywords

Malignant lymphatic disease; therapy-reality; observation; registry; therapy sequences; NHL; CLL; Germany; lenalidomide; alemtuzumab; rituximab; bendamustin; thalidomide; bortezomib; ibritumomab-tiuxetan; G-CSF (Granulocyte-Colony Stimulating Factor); chronic lymphocytic leukaemia; follicular lymphoma; gastric MALT lymphoma (Mucosa Associated Lymphoid Tissue); nongastric MALT lymphoma (Mucosa Associated Lymphoid Tissue); nodal marginal zone lymphoma; splenic marginal zone lymphoma; mantle cell lymphoma; diffuse large b-cell lymphoma

Outcome Measures

Primary Outcomes (1)

• Course of treatment (treatment reality)

  Documentation of anamnestic data and therapy sequences

  5 years per patient

Secondary Outcomes (1)

• Effectiveness of treatment

  5 years per patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with a malignant lymphatic disease requiring therapy

You may qualify if:

• Confirmed diagnosis of Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia or multiple myeloma
• Must receive a first- or second-line therapy
• years or older
• Signed, written informed consent

You may not qualify if:

• \- no systemic therapy

Sponsors & Collaborators

• iOMEDICO AG: lead

Related Publications (5)

• Knauf W, Abenhardt W, Dorfel S, Meyer D, Grugel R, Munz M, Hartmann H, Marschner N. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015 Mar;33(1):15-22. doi: 10.1002/hon.2139. Epub 2014 Apr 15.

  PMID: 24733536 RESULT

• Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Munz M, Hartmann H, Marschner N; TLN Study Group. Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17.

  PMID: 25486127 RESULT

• Knauf W, Aldaoud A, Hutzschenreuter U, Klausmann M, Dille S, Wetzel N, Janicke M, Marschner N; and the TLN-Group (Tumour Registry Lymphatic Neoplasms). Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol. 2018 Dec;97(12):2437-2445. doi: 10.1007/s00277-018-3449-8. Epub 2018 Aug 1.

  PMID: 30069704 RESULT

• Knauf W, Abenhardt W, Mohm J, Rauh J, Harde J, Kaiser-Osterhues A, Janicke M, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol. 2019 Nov;103(5):460-471. doi: 10.1111/ejh.13295. Epub 2019 Sep 4.

  PMID: 31314918 RESULT

• Knauf W, Abenhardt W, Slawik HR, Buckner U, Otremba B, Sauer A, Zahn MO, Wetzel N, Kaiser-Osterhues A, Houet L, Marschner N; TLN-Group (Tumour Registry Lymphatic Neoplasms). Rare lymphomas in routine practice-Treatment and outcome in Waldenstrom's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2020 Aug;38(3):344-352. doi: 10.1002/hon.2740. Epub 2020 May 8.

  PMID: 32383192 RESULT

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Leukemia, B-Cell; Lymphoma, Follicular; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Large B-Cell, Diffuse

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, Lymphoid; Leukemia; Hematologic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Lymphoma, B-Cell

Study Officials

• Wolfgang Knauf, MD

  Center for Haematology, Frankfurt, Germany

  STUDY CHAIR

• Wolfang Abenhardt, MD

  MVZ Onkologie im Elisenhof, München, Germany

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 5 Years
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2009
• First Posted: April 29, 2009
• Study Start: April 1, 2009
• Primary Completion: August 31, 2019
• Study Completion: August 31, 2019
• Last Updated: May 18, 2020

Record last verified: 2020-05

Data Sharing

• IPD Sharing: Will not share